Anna C Calkin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7114411/publications.pdf

Version: 2024-02-01

59	4,133	185998	143772
papers	citations	28 h-index	57 g-index

67	67	67	6627
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease. Frontiers in Physiology, 2022, 13, 839471.	1.3	4
2	A roadmap of strategies to support cardiovascular researchers: from policy to practice. Nature Reviews Cardiology, 2022, 19, 765-777.	6.1	6
3	Deletion of Trim28 in committed adipocytes promotes obesity but preserves glucose tolerance. Nature Communications, 2021, 12, 74.	5.8	16
4	LACK OF FUNDING AND LONG-TERM JOB SECURITY THREATENS TO HAVE PROFOUND EFFECTS ON CARDIOVASCULAR RESEARCHER RETENTION IN AUSTRALIA. Journal of Hypertension, 2021, 39, e12.	0.3	0
5	The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol. Metabolites, 2021, 11, 340.	1.3	3
6	Loss of the long non-coding RNA OIP5-AS1 exacerbates heart failure in a sex-specific manner. IScience, 2021, 24, 102537.	1.9	12
7	FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metabolism, 2021, 33, 1671-1684.e4.	7.2	165
8	Genome-Wide Association Study Identifies a Functional SIDT2 Variant Associated With HDL-C (High-Density Lipoprotein Cholesterol) Levels and Premature Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2494-2508.	1.1	10
9	Lipin 1 modulates mRNA splicing during fasting adaptation in liver. JCI Insight, 2021, 6, .	2.3	7
10	Tissue-specific expression of Cas9 has no impact on whole-body metabolism in four transgenic mouse lines. Molecular Metabolism, 2021, 53, 101292.	3.0	5
11	SOD2 in skeletal muscle: New insights from an inducible deletion model. Redox Biology, 2021, 47, 102135.	3.9	14
12	Apolipoprotein A-I for Cardiac Recovery Postâ€“Myocardial Infarction. JACC Basic To Translational Science, 2021, 6, 768-771.	1.9	2
13	Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases. Nature Metabolism, 2021, 3, 1476-1483.	5.1	43
14	Sex differences in white adipose tissue expansion: emerging molecular mechanisms. Clinical Science, 2021, 135, 2691-2708.	1.8	10
15	Addressing Gender Equity in Senior Leadership Roles in Translational Science. ACS Pharmacology and Translational Science, 2020, 3, 773-779.	2.5	9
16	Lack of Strategic Funding and Long-Term Job Security Threaten to Have Profound Effects on Cardiovascular Researcher Retention in Australia. Heart Lung and Circulation, 2020, 29, 1588-1595.	0.2	10
17	Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease. Frontiers in Physiology, 2020, 11, 518.	1.3	3
18	The Antioxidant Moiety of MitoQ Imparts Minimal Metabolic Effects in Adipose Tissue of High Fat Fed Mice. Frontiers in Physiology, 2019, 10, 543.	1.3	29

#	Article	IF	Citations
19	An integrative systems genetic analysis of mammalian lipid metabolism. Nature, 2019, 567, 187-193.	13.7	101
20	IDOL regulates systemic energy balance through control of neuronal VLDLR expression. Nature Metabolism, 2019, 1, 1089-1100.	5.1	12
21	The E3 ligase MARCH5 is a PPARÎ³ target gene that regulates mitochondria and metabolism in adipocytes. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E293-E304.	1.8	19
22	Compression force sensing regulates integrin Î±IIbÎ²3 adhesive function on diabetic platelets. Nature Communications, 2018, 9, 1087.	5.8	39
23	The CCC Complex COMManDs Control of LDL Cholesterol Levels. Circulation Research, 2018, 122, 1629-1631.	2.0	1
24	The Use of L-sIDOL Transgenic Mice as a Murine Model to Study Hypercholesterolemia and Atherosclerosis. Methods in Molecular Biology, 2017, 1583, 65-72.	0.4	1
25	Thrombosis in diabetes: a shear flow effect?. Clinical Science, 2017, 131, 1245-1260.	1.8	25
26	Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy. Journal of Molecular Endocrinology, 2017, 58, R225-R240.	1.1	50
27	Novel regulation of lipid metabolism. Impact, 2017, 2017, 37-39.	0.0	0
28	Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 295-307.	1.1	147
29	Estrogen Receptor (ER)Î±-regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression. Journal of Biological Chemistry, 2015, 290, 5566-5581.	1.6	61
30	Transgenic Expression of Dominant-Active IDOL in Liver Causes Diet-Induced Hypercholesterolemia and Atherosclerosis in Mice. Circulation Research, 2014, 115, 442-449.	2.0	21
31	Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. Diabetologia, 2013, 56, 1155-1165.	2.9	34
32	Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nature Reviews Molecular Cell Biology, 2012, 13, 213-224.	16.1	616
33	Large artery biomechanics and diastolic dysfunctionin patients with Type 2 diabetes. Diabetic Medicine, 2011, 28, 54-60.	1.2	22
34	Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia, 2011, 54, 681-689.	2.9	61
35	FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20107-20112.	3.3	53
36	The IDOLâ€“UBE2D complex mediates sterol-dependent degradation of the LDL receptor. Genes and Development, 2011, 25, 1262-1274.	2.7	75

#	Article	IF	Citations
37	The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans. Journal of Clinical Investigation, 2011, 121, 3062-3071.	3.9	50
38	Genome-Wide Association Studies Identify New Targets in Cardiovascular Disease. Science Translational Medicine, 2010, 2, 48ps46.	5.8	18
39	Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-Î² in a murine diabetic model of atherosclerosis. Diabetologia, 2010, 53, 170-179.	2.9	32
40	The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. American Journal of Physiology - Renal Physiology, 2010, 299, F528-F535.	1.3	36
41	Liver X Receptor Signaling Pathways and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1513-1518.	1.1	257
42	Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine Tail. Diabetes, 2009, 58, 1229-1236.	0.3	468
43	Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux. Circulation, 2009, 120, 2095-2104.	1.6	167
44	Direct antiatherosclerotic effects of PPAR agonists. Current Opinion in Lipidology, 2009, 20, 24-29.	1.2	29
45	The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia, 2008, 51, 1731-1740.	2.9	57
46	Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes. Diabetes, 2008, 57, 2461-2469.	0.3	376
47	PPAR Agonists and Cardiovascular Disease in Diabetes. PPAR Research, 2008, 2008, 1-12.	1.1	25
48	Lack of the Antioxidant Enzyme Glutathione Peroxidase-1 Accelerates Atherosclerosis in Diabetic Apolipoprotein Eâ€“Deficient Mice. Circulation, 2007, 115, 2178-2187.	1.6	233
49	PPARs and Diabetes-Associated Atherosclerosis. Current Pharmaceutical Design, 2007, 13, 2736-2741.	0.9	8
50	Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis, 2007, 195, 17-22.	0.4	41
51	The clot thickensâ€”oxidized lipids and thrombosis. Nature Medicine, 2007, 13, 1015-1016.	15.2	23
52	Diabetes Mellitus-Associated Atherosclerosis. American Journal of Cardiovascular Drugs, 2006, 6, 15-40.	1.0	26
53	Vildagliptin. Drugs, 2006, 66, 2002-2004.	4.9	1
54	Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia, 2006, 49, 766-774.	2.9	72

#	Article	IF	Citations
55	PPAR-Î± and -Î³ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrology Dialysis Transplantation, 2006, 21, 2399-2405.	0.4	101
56	Imatinib Attenuates Diabetic Nephropathy in Apolipoprotein E-Knockout Mice. Journal of the American Society of Nephrology: JASN, 2005, 16, 363-373.	3.0	121
57	Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1903-1909.	1.1	120
58	Accelerated Nephropathy in Diabetic Apolipoprotein E-Knockout Mouse: Role of Advanced Glycation End Products. Journal of the American Society of Nephrology: JASN, 2004, 15, 2125-2138.	3.0	137
59	Rapid Potentiation of Endothelium-Dependent Vasodilation by Estradiol in Postmenopausal Women Is Mediated via Cyclooxygenase 2. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5072-5075.	1.8	38